The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics
- PMID: 17568191
- DOI: 10.4161/cc.6.11.4353
The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics
Abstract
Prostatic adenocarcinomas are dependent on androgen receptor (AR) signaling for growth and progression, in part through the ability of AR to induce G1-S phase cell cycle transition. Hormonal therapies that inhibit AR activity are the first line of intervention for disseminated disease, and are initially quite effective; however, recurrent, incurable tumors ultimately arise with restored AR function. Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival. Recent studies have challenged the utility of manipulating AR activity to enhance cell death in combination with genotoxic insult. Herein, the role of AR in controlling cell cycle progression and paradoxical roles of AR in survival signals are considered, as are the potential implications of these findings for chemotherapeutic response. Although there is much to be resolved, the present data suggest that knowledge of AR action in promoting cellular proliferation can be utilized for the design of coordinate strategies that maximize cell death in response to cytotoxic chemotherapeutics.
Similar articles
-
[Prostate cancer and apoptosis].Invest Clin. 2011 Dec;52(4):376-96. Invest Clin. 2011. PMID: 22523847 Review. Spanish.
-
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.Cancer Res. 2000 Dec 1;60(23):6630-40. Cancer Res. 2000. PMID: 11118046
-
Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.Int J Cancer. 2010 Feb 1;126(3):775-89. doi: 10.1002/ijc.24806. Int J Cancer. 2010. PMID: 19653278
-
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.Cancer Sci. 2011 Nov;102(11):2022-8. doi: 10.1111/j.1349-7006.2011.02043.x. Epub 2011 Aug 18. Cancer Sci. 2011. PMID: 21781227 Free PMC article.
-
AR, the cell cycle, and prostate cancer.Nucl Recept Signal. 2008 Feb 1;6:e001. doi: 10.1621/nrs.06001. Nucl Recept Signal. 2008. PMID: 18301781 Free PMC article. Review.
Cited by
-
Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.Neoplasia. 2008 May;10(5):418-28. doi: 10.1593/neo.07985. Neoplasia. 2008. PMID: 18472959 Free PMC article.
-
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706803 Free PMC article.
-
A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model.Cancer Prev Res (Phila). 2010 Jul;3(7):885-95. doi: 10.1158/1940-6207.CAPR-09-0273. Epub 2010 Jun 29. Cancer Prev Res (Phila). 2010. PMID: 20587701 Free PMC article.
-
Targeting silencing androgen receptor gene by shRNA with low-intensity focused ultrasonic irradiation inhibits growth of prostate cancer xenografts in nude mice.Int J Clin Exp Pathol. 2019 Apr 1;12(4):1295-1304. eCollection 2019. Int J Clin Exp Pathol. 2019. PMID: 31933943 Free PMC article.
-
Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers.Mol Cancer Ther. 2022 Feb;21(2):294-309. doi: 10.1158/1535-7163.MCT-21-0411. Epub 2021 Nov 23. Mol Cancer Ther. 2022. PMID: 34815359 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials